title: Circulating CD14++CD16+ Monocyte Subsets as a Surrogate Marker of the Therapeutic Effect of Corticosteroid Therapy in Patients With Cardiac Sarcoidosis.
abstract: BACKGROUND
  We aimed to evaluate whether specific monocyte subsets could serve as surrogate markers of disease activity in cardiac sarcoidosis (CS) evaluated by 18F-fluoro-2-deoxyglucose positron emission tomography (18F-FDG PET).
  
  
  RESULTS
  We studied 28 patients with CS (8 men; mean age: 61±9 years) diagnosed according to consensus criteria. We divided the patients into 2 groups: known CS receiving corticosteroid therapy (Rx(+); n=13) and new-onset CS (Rx(-); n=15), and analyzed 3 distinct monocyte subsets (CD14+CD16-, CD14++CD16+, and CD14+ -CD16+). Monocyte subsets were also analyzed in 10 Rx(-) patients before and 12 weeks after starting corticosteroid therapy. Inflammatory activity was quantified by 18F-FDG PET using the coefficient of variation (COV) of the standardized uptake value (SUV). The proportion of CD14++CD16+ monocytes in Rx(+) patients (10.8 [0.2-23.5] %) was significantly lower than in Rx(-) patients (23.0 [11.5-38.4] %, P=0.001). After corticosteroid therapy, the COV of the SUV was significantly improved from 0.32 [0.14-0.62] to 0.17 [0.04-0.43] (P=0.017). The proportion of CD14++16+ monocytes showed a significant decrease from 22.2 [8.8-38.4] % to 8.4 [1.8-16.8] % (P=0.001). The decrease in the proportion of CD14++16+ monocytes significantly correlated with the decrease in the COV of the SUV (r=0.495, P=0.027).
  
  
  CONCLUSIONS
  CD14++16+ monocytes are a possible surrogate marker of the therapeutic effect of corticosteroid therapy in CS.
authors.affiliation: Department of Cardiovascular Medicine, Wakayama Medical University.
authors.forename: Makoto
authors.initials: M
authors.lastname: Orii
authors.forename: Toshio
authors.initials: T
authors.lastname: Imanishi
authors.forename: Ikuko
authors.initials: I
authors.lastname: Teraguchi
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Nishiguchi
authors.forename: Yasutsugu
authors.initials: Y
authors.lastname: Shiono
authors.forename: Takashi
authors.initials: T
authors.lastname: Yamano
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Ino
authors.forename: Kumiko
authors.initials: K
authors.lastname: Hirata
authors.forename: Takashi
authors.initials: T
authors.lastname: Kubo
authors.forename: Atsushi
authors.initials: A
authors.lastname: Tanaka
authors.forename: Takashi
authors.initials: T
authors.lastname: Akasaka
mesh_terms: D000305:Adrenal Cortex Hormones / Q000008:administration & dosage*; D000368:Aged; D015415:Biomarkers / Q000097:blood; D009202:Cardiomyopathies / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy; D005260:Female; D058851:GPI-Linked Proteins / Q000097:blood; D019298:Glucose-6-Phosphate / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D018950:Lipopolysaccharide Receptors / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009000:Monocytes / Q000378:metabolism*; D049268:Positron-Emission Tomography; D011859:Radiography; D017452:Receptors, IgG / Q000097:blood*; D012507:Sarcoidosis / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy
chemical_list: D000305:Adrenal Cortex Hormones; D015415:Biomarkers; C428200:FCGR3B protein, human; D058851:GPI-Linked Proteins; D018950:Lipopolysaccharide Receptors; D017452:Receptors, IgG; C047515:2-fluoro-2-deoxyglucose-6-phosphate; D019298:Glucose-6-Phosphate